CSF Tau proteins reduce misdiagnosis of sporadic Creutzfeldt-Jakob disease suspected cases with inconclusive 14-3-3 result.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27357003)

Published in J Neurol on June 29, 2016

Authors

M J Leitão1,2, I Baldeiras3,4,5, M R Almeida5, M H Ribeiro3,4, A C Santos5, M Ribeiro5, J Tomás6, S Rocha7, I Santana6,4,5, C R Oliveira3,6,4,5

Author Affiliations

1: Neurochemistry Laboratory, Neurology Department, University Hospital Coimbra, Centro Hospitalar e Universitário de Coimbra, Praceta Mota Pinto, 3000-075, Coimbra, Portugal. jajao86@gmail.com.
2: CNC.IBILI-Center for Neuroscience and Cell Biology, University of Coimbra, Rua Larga, 1st floor, 3004-504, Coimbra, Portugal. jajao86@gmail.com.
3: Neurochemistry Laboratory, Neurology Department, University Hospital Coimbra, Centro Hospitalar e Universitário de Coimbra, Praceta Mota Pinto, 3000-075, Coimbra, Portugal.
4: Faculty of Medicine, University of Coimbra, Faculdade de Medicina, Pólo III, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal.
5: CNC.IBILI-Center for Neuroscience and Cell Biology, University of Coimbra, Rua Larga, 1st floor, 3004-504, Coimbra, Portugal.
6: Neurology Department, University Hospital Coimbra, Centro Hospitalar e Universitário de Coimbra, Praceta Mota Pinto, 3000-075, Coimbra, Portugal.
7: Neurology Department, St Marcos Hospital, Sete Fontes, São Victor, 4710-243, Braga, Portugal.

Articles cited by this

Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med (2011) 3.95

Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. Arch Neurol (2003) 3.20

Rapidly progressive dementia. Ann Neurol (2008) 3.00

A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease. Neurology (2012) 2.66

Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain (2006) 2.54

Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol (1998) 2.35

The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: a 10-year review. J Neurol Neurosurg Psychiatry (2010) 2.29

CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology (2006) 2.19

Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease. Ann Neurol (2012) 2.18

Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol (1995) 2.10

Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Brain (2004) 1.96

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87

Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology (2002) 1.84

Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt-Jakob disease. Neurology (2000) 1.82

Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry. JAMA Neurol (2014) 1.79

CSF detection of the 14-3-3 protein in unselected patients with dementia. Neurology (2001) 1.76

Total tau protein in cerebrospinal fluid and diffusion-weighted MRI as an early diagnostic marker for Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord (2007) 1.72

How to improve the clinical diagnosis of Creutzfeldt-Jakob disease. Brain (1999) 1.71

Single-day apolipoprotein E genotyping. J Neurosci Methods (1994) 1.59

Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry (2003) 1.58

Creutzfeldt-Jakob disease in Germany: a prospective 12-year surveillance. Brain (2007) 1.56

Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease. JAMA Neurol (2015) 1.51

Establishment of a standard 14-3-3 protein assay of cerebrospinal fluid as a diagnostic tool for Creutzfeldt-Jakob disease. Lab Invest (2010) 1.35

A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry (2003) 1.27

Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. Brain (2012) 1.24

Diagnostic accuracy of cerebrospinal fluid protein markers for sporadic Creutzfeldt-Jakob disease in Canada: a 6-year prospective study. BMC Neurol (2011) 1.24

14-3-3 CSF levels in sporadic Creutzfeldt-Jakob disease differ across molecular subtypes. Neurobiol Aging (2008) 1.18

Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci Lett (1999) 1.17

14-3-3 testing in diagnosing Creutzfeldt-Jakob disease: a prospective study in 112 patients. Neurology (2000) 1.14

An enzyme-linked immunosorbent assay to quantify 14-3-3 proteins in the cerebrospinal fluid of suspected Creutzfeldt-Jakob disease patients. Ann Neurol (2000) 1.10

The role of cerebrospinal fluid proteins as early diagnostic markers for sporadic Creutzfeldt-Jakob disease. Neurosci Lett (2009) 1.03

Phosphorylated tau in cerebrospinal fluid as a marker for Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry (2002) 1.02

A Practical Guide to Immunoassay Method Validation. Front Neurol (2015) 1.02

Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. Neurobiol Aging (2006) 1.00

Intensity of human prion disease surveillance predicts observed disease incidence. J Neurol Neurosurg Psychiatry (2013) 1.00

The diagnostic efficiency of biomarkers in sporadic Creutzfeldt-Jakob disease compared to Alzheimer's disease. Neurobiol Aging (2008) 0.99

Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease? J Neurol Neurosurg Psychiatry (2001) 0.97

Validation of 14-3-3 Protein as a Marker in Sporadic Creutzfeldt-Jakob Disease Diagnostic. Mol Neurobiol (2015) 0.95

Diagnostic value of CSF protein profile in a Portuguese population of sCJD patients. J Neurol (2009) 0.94

Comparative analysis of cerebrospinal fluid biomarkers in the differential diagnosis of neurodegenerative dementia. Alzheimers Dement (2015) 0.92

Genetic cross-interaction between APOE and PRNP in sporadic Alzheimer's and Creutzfeldt-Jakob diseases. PLoS One (2011) 0.89

14-3-3 in the cerebrospinal fluid of patients with variant and sporadic Creutzfeldt-Jakob disease measured using capture assay able to detect low levels of 14-3-3 protein. Neurosci Lett (2002) 0.86

Chasing the Effects of Pre-Analytical Confounders - A Multicenter Study on CSF-AD Biomarkers. Front Neurol (2015) 0.86

High sensitivity of an ELISA kit for detection of the gamma-isoform of 14-3-3 proteins: usefulness in laboratory diagnosis of human prion disease. BMC Neurol (2011) 0.85

Cerebrospinal fluid tau levels are a marker for molecular subtype in sporadic Creutzfeldt-Jakob disease. Neurobiol Aging (2015) 0.85

Serum tau protein as a marker for the diagnosis of Creutzfeldt-Jakob disease. J Neurol (2011) 0.84

Variant Creutzfeldt-Jakob [corrected] disease: the second case in Portugal and in the same geographical region. J Neurol Neurosurg Psychiatry (2007) 0.76

Sporadic Creutzfeldt-Jakob disease causing a 2-years slowly progressive isolated dementia. Behav Neurol (2009) 0.76

Sporadic Creutzfeldt-Jakob disease diagnostic accuracy is improved by a new CSF ELISA 14-3-3γ assay. Neuroscience (2016) 0.76

Cerebrospinal fluid Aβ40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease. J Neurol Sci (2015) 0.76

Alternative application of Tau protein in Creutzfeldt-Jakob disease diagnosis: Improvement for weakly positive 14-3-3 protein in the laboratory. Sci Rep (2015) 0.76

Facilitating the Validation of Novel Protein Biomarkers for Dementia: An Optimal Workflow for the Development of Sandwich Immunoassays. Front Neurol (2015) 0.76